Can Boehringer carve out space in a crowded COPD market with new approval?

Carly Helfand The COPD market has its fair share of contenders, but that's not stopping Boehringer Ingelheim from joining the party. The German drugmaker has nabbed FDA approval ...

Teva gets more than half of U.S. Copaxone patients converted to long-lasting version

Eric Palmer One of the key strategies being pursued by Teva Pharmaceutical Industries to protect itself against generic competition to Copaxone is to switch patients over to its new ...

Loxo pulls off a $68M IPO to bankroll its cancer pipeline

Damian Garde Connecticut's Loxo Oncology nailed down about $ 68 million in an up-sized IPO, filling its coffers as it works up some targeted cancer therapies. FierceBiotech News

Lilly, Boehringer win FDA approval for once-rejected diabetes drug

Damian Garde After a manufacturing issue scuttled their first attempt, Eli Lilly and Boehringer Ingelheim have won the FDA's blessing to market their new diabetes drug, a late entrant ...

FDA comes around on Boehringer, Lilly’s diabetes med Jardiance

Carly Helfand The FDA is changing its tune on Jardiance, a Boehringer Ingelheim diabetes med it hasn't been so keen on in the past. After rejecting the drug in the ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS